We serve Polysiloxanes di-Me Me hydrogen CAS:68037-59-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:Polysiloxanes di-Me Me hydrogen
CAS.NO:68037-59-2
Synonyms:DIMETHYLSILOXANE COPOLYMER, TRIMETHYLSILOXANE TERMINATED;
METHYLHYDROSILOXANE, DIMETHYLSILOXANE COPOLYMER, TRIMETHYLSILOXANE TERMINATED
Molecular Formula:C3H12OSi2
Molecular Weight:120.29778
Specification:
Appearance:White powder
Purity(GC):≥99.0%
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Base powder for makeup
Contact us for information like Polysiloxanes di-Me Me hydrogen chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,TRIMETHYLSILOXANE TERMINATED physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,DIMETHYLSILOXANE COPOLYMER, TRIMETHYLSILOXANE TERMINATED Use and application,DIMETHYLSILOXANE COPOLYMER technical grade,usp/ep/jp grade.
Related News: Any South Korean citizen returning home who has been in Hubei Province within the past two weeks will be subject to 14 days of self-quarantine and monitoring, the government said.Tetrachloropropene manufacturer Any South Korean citizen returning home who has been in Hubei Province within the past two weeks will be subject to 14 days of self-quarantine and monitoring, the government said.2-Hydroxy-3-methyl-2-cyclopentenone supplier As one of the world’s largest API producers and exporters, China’s chemical API production and operating income show steady growth.3-Chloropivaloyl Chloride vendor Multinational drugmakers usually cut the price of drugs when they go off-patent and face competition from generic versions, but such price drops were slow to happen in China, partially because many local drugmakers were unable to develop high-quality generic drugs to compete with off-patent branded drugs.Multinational drugmakers usually cut the price of drugs when they go off-patent and face competition from generic versions, but such price drops were slow to happen in China, partially because many local drugmakers were unable to develop high-quality generic drugs to compete with off-patent branded drugs.
